BRD2 and neoplasm: Indeed, the NAT period represents an invaluable window of opportunity to gather both longitudinal data (such as kinetics of tumor size, pharmacodynamic markers, or circulating DNA from liquid biopsies), as well as single-time biomarkers from the tumor tissue [2].